Ig Vena

Human normal immunoglobulin, the active ingredient in Ig Vena, is an immunoglobulin presented as an intravenous solution for intravenous use. It treats primary and secondary immunodeficiency diseases, immune thrombocytopenic purpura (ITP), and Kawasaki disease.

GNH USA supplies Ig Vena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Ig Vena is used in immunoglobulin replacement therapy to restore antibody levels in various immune‑mediated conditions.

- Primary immunodeficiency diseases: provides passive immunity and reduces infection frequency. - Secondary immunodeficiency: supplements deficient IgG to protect against opportunistic infections. - Immune thrombocytopenic purpura (ITP): helps raise platelet counts by modulating immune response. - Kawasaki disease: reduces inflammation and coronary artery complications in the acute phase.

Ig Vena may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Fever or chills: low‑grade temperature elevation during infusion. - Nausea: occasional gastrointestinal discomfort. - Fatigue: generalized tiredness post‑infusion. - Injection site reactions: redness or swelling at the IV site.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Thromboembolic events: clot formation in veins or arteries. - Acute renal failure: sudden loss of kidney function. - Hemolysis: destruction of red blood cells. - Aseptic meningitis: inflammation of meninges without infection.

When using Ig Vena, clinicians should observe specific precautions to minimize risks and ensure optimal therapy. - Assess patient history: screen for IgA deficiency and prior severe reactions to immunoglobulins. - Monitor vital signs: observe blood pressure, heart rate, and temperature during and after infusion. - Adjust infusion rate: start slowly and increase gradually to reduce infusion‑related reactions. - Concomitant anticoagulants: evaluate bleeding risk when patients receive anticoagulant therapy. - Renal function: check baseline creatinine and maintain adequate hydration. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ig Vena can interact with other medicines, affecting safety or efficacy.

Major Interactions (Avoid): - Live vaccines: concurrent administration may increase risk of infection. - High‑dose aspirin or NSAIDs: may heighten bleeding tendency during infusion.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., rituximab): may reduce the effectiveness of Ig therapy. - Corticosteroids: may mask early signs of infusion reactions. - Anticoagulants (warfarin, heparin): monitor coagulation parameters. - Diuretics: ensure adequate hydration to protect renal function.